News

Bin et al isolated and characterized 206 potential therapeutic and prophylactic monoclonal Abs from 8 COVID-19 patients. The isolated Abs were found to prevent RBD-ACE-2 interaction and to have high binding affinity and neutralizing activity...

Cao et al., describe a promising clinical outcome of three patients presenting with severe COVID-19 and treated with high-dose intravenous immunoglobulin (IVIg). According to the authors "All patients were clinically improved shortly following the administration...

In an attempt to avoid repeating the mistakes of the 2014–16 West African Ebola epidemic, where clinical trials were set up late, leading to the under-recruiting of patients – in the current pandemic researchers have decided to start trials as soon as possible...

One explanation for the milder COVID-19 disease presentation in children may be that children have a qualitatively different response to the SARS-CoV2 virus to adults (1). Another possibility is the common simultaneous presence of additional viruses in the mucosa of lungs and airways of young children...

In an unprecedented effort to obtain scientific data during the SARS-CoV-2 pandemic, the World Health Organization (WHO) has announced the new SOLIDARITY trial that would include thousands of patients from around the world (45 countries and counting)...

Biological factors that determine susceptibility to SARS-CoV-2 and severity of COVID-19 are yet to be fully understood. A pre-print released in medRxiv by Zhao et al suggests that the ABO blood grouping may influence acquisition of COVID-19 and severity of the disease.

Retrospective analysis of COVID-19 patient history showed that 12-22% and 23-30% of severe COVID-19 patients also had diabetes and hypertension, respectively. This and other reports suggest that hypertension and diabetes are associated with a high risk of severe COVID-19.

Andersen et al have described the genomic structure of SARS-CoV-2. Notably, the virus has a receptor binding domain consisting of 6 amino acids which not only differentiates it from SARS-CoV but also confers it with ability to bind human or human-like Angiotensin Converting Enzyme-1 (ACE2) with high affinity.

Since the SARS-CoV-2 virus started to circulate in the different countries that the COVID-19 pandemic has reached, a possible seasonal pattern in the presentation of the disease has been hypothesized. T study the seasonality of diseases, researchers normally focus on several factors...

27 MarchSheahan et al recently pre-published a paper that states that ribonucleoside analog β-D-N4-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV 2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoV.